Quality Project to Evaluate and Validate the FAST-O Rating Scale

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00913731
First received: June 2, 2009
Last updated: October 28, 2009
Last verified: October 2009

June 2, 2009
October 28, 2009
May 2009
Not Provided
Reliability test of the FAST-O rating scale based on observational symptom ratings of patients with acute psychotic diseases [ Time Frame: Each patients symtoms will be rated on 2 occasions, by 2-3 raters, each. First is made within 24 hrs of admission to acute psychiatric care, secondis made 14 +/- 2 days after admittance, or earlier if the patient is discharged. ] [ Designated as safety issue: No ]
Reliability test of the FAST-O rating scale based on observational symptom ratings of patients with acute psychotic diseases [ Time Frame: Each patient will be assessed on 2-3 occasions ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00913731 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Quality Project to Evaluate and Validate the FAST-O Rating Scale
Quality Project to Evaluate and Validate the FAST-O Rating Scale (Fast ASessment in Acute Treatment of Psychosis-Observation)

The purpose of this project is to test the reliability of the FAST-O Rating Scale in patients at acute wards or psychiatric intensive care units.

Not Provided
Observational
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

Patients with acute psychotic symptoms attending the acute ward or psychiatric intensive care unit

Acute Psychotic Symptoms
Not Provided
psychotic patients
psychotic patients, acute ward, symptom rating scale.
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
111
October 2009
Not Provided

Inclusion Criteria:

  • Patients with acute psychotic symptoms attending the acute ward or psychiatric intensive care unit

Exclusion Criteria:

  • Not applicable
Both
Not Provided
No
Contact information is only displayed when the study is recruiting subjects
Sweden
 
NCT00913731
NIS-NSE-DUM-2008/1
No
AstraZeneca
AstraZeneca
Not Provided
Study Director: Eva Dencker Vansvik Medical Department
Principal Investigator: Eva Lindström Rättspsyk, UMAS, Malmö
AstraZeneca
October 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP